Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

This publication has 21 references indexed in Scilit:

• New targets for pyrimidine antimetabolites for the treatment of solid tumours
  Pharmacy World & Science, 1994
• 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
  Biochemical Pharmacology, 1993
• The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
  British Journal of Cancer, 1993
• Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)
  Cancer Treatment Reviews, 1993
• A quantitative assay for fragmented DNA in apoptotic cells
  Analytical Biochemistry, 1992
• Modulation of deoxycytidylate deaminase in intact human leukemia cells: Action of 2',2'-difluorodeoxycytidine
  Biochemical Pharmacology, 1992
• Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells
  Gynecologic Oncology, 1992
• Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
  Cancer Chemotherapy and Pharmacology, 1991
• 2',2'-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells
  Nucleosides, Nucleotides and Nucleic Acids, 1989
• Deoxycytidine Kinase
  Published by Elsevier ,1970